title: [Use of levamisole in W. bancrofti filariasis].
abstract: 16 african patients with diagnosed W. bancroft's filariasis admitted to Pedro Kourí Tropical Medicine Institute were subjected to a therapeutic management with levamisole: 300 mg as starting dosage, and 150 mg/day for seven days. 11 patients had been previously treated with several courses of diethylcarbamazine (DEC), but a low microfilaremia persisted in them. In the other 5 patients the only medication used was levamisole. A rapid fall in microfilaria concentrations was found from the first day of treatment on in all patients. Eventually, 14 patients (87,5%) were negative and two patients (12,5%) persisted having low microfilaremia and their concentrations lowered by 89 ad 93% respectively.
mesh_terms: D000293:Adolescent; D000328:Adult; D004049:Diethylcarbamazine / Q000627:therapeutic use; D004341:Drug Evaluation; D005260:Female; D005368:Filariasis / Q000188:drug therapy*; D006801:Humans; D007978:Levamisole / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008842:Microfilariae / Q000187:drug effects; D014958:Wuchereria bancrofti
chemical_list: D007978:Levamisole; D004049:Diethylcarbamazine
vernacular_title: Uso del levamisol en la filariasis por W. bancrofti.